Navigation Links
Gene therapy demonstrates benefit in patients with rheumatoid arthritis
Date:1/26/2009

BOSTON -- Researchers have reported the first clinical evidence that gene therapy reduces symptoms in patients with rheumatoid arthritis, an important milestone for this promising treatment which has endured a sometimes turbulent past. Described in the February issue of the journal Human Gene Therapy the findings stem from a study of two patients with severe rheumatoid arthritis conducted in Germany and led by an investigator at Beth Israel Deaconess Medical Center (BIDMC).

Originally conceived as a means of treating genetic diseases, such as cystic fibrosis and hemophilia, gene therapy involves implanting a normal gene to compensate for a defective gene in the patient. The first clinical trial to test gene therapy was launched in 1990 for the treatment of a rare, genetic immunodeficiency disease.

"This study helps extend gene therapy research to nongenetic, nonlethal diseases," explains principal investigator Christopher Evans, PhD, Director of the Center for Advanced Orthopaedic Studies at BIDMC. "Rheumatoid arthritis [RA] is an extremely painful condition affecting multiple joints throughout the body. Arthritis is a good target for this treatment because the joint is a closed space into which we can inject genes," adds Evans, who is also the Maurice Muller Professor of Orthopaedic Surgery at Harvard Medical School.

A classic autoimmune disease, RA develops when, for unknown reasons, the body's immune system turns against itself, causing joints to become swollen and inflamed. If the disease is inadequately controlled, the tissues of the joint are eventually destroyed. Although anti-inflammatory agents and biologics can help to mitigate symptoms, there is no cure for the condition, estimated to affect more than 2 million individuals in the U.S. alone.

Evans has spent many years studying the molecules responsible for the breakdown of cartilage in patients with arthritis, identifying interleukin-1 as a good target.
'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. A new radiation therapy treatment developed for head and neck cancer patients
2. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
3. UC health news: molecular pathway may predict chemotherapy effectiveness
4. MIT works toward safer gene therapy
5. Intravenous gene therapy protects normal tissue of mice during whole-body radiation
6. Gene, stem cell therapy only needs to be 50 percent effective to create a healthy heart
7. Fourth Annual International Conference on Cell Therapy for Cardiovascular Diseases
8. Safe and effective therapy discovered for patients with protein-losing enteropathy
9. Ireland Cancer Center researchers advance stem cell gene therapy
10. Dolphin therapy a dangerous fad, Emory researchers warn
11. Cancer and arthritis therapy may be promising treatment for diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... 20, 2014   Atmel® Corporation (NASDAQ: ... and touch technology solutions, today launched the industry,s first ... the widest V cc range from 1.7V to ... faster I 2 C bus communication speeds, and are ... making them ideal for consumer, industrial, computer, and medical ...
(Date:11/18/2014)...   EyeLock Inc. , a market leader ... USA (Safran), a leading U.S. provider of ... partnership to offer comprehensive biometric identity solutions and ... screening and financial services markets. As ... through a nationwide network of 1,100 IdentoGO® Centers.  ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... and other senior female family members should play a key ... in non-Western societies. However, they are often overlooked by health ... see them as an obstacle to promoting good nutrition and ... extensive literature review published in the January issue of ...
... celebrates its 50,000th eBook, available on its online ... Springer,s position as the largest eBook publisher and ... comprehensive online collection of science, technology and medicine ... addition, as announced in October 2011, Springer will ...
... may soon benefit from an experimental drug being tested by ... Texas A&M College of Veterinary Medicine & Biomedical Sciences ... similar injuries. Funded through a three-year, $750,000 grant from ... has already proven effective in mice at UCSF. Now the ...
Cached Biology News:Research highlights key role grandmothers play in mother and child nutrition and health 2Research highlights key role grandmothers play in mother and child nutrition and health 3SpringerLink now offers more than 50,000 eBooks 2Saving dogs with spinal cord injuries 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Cytochroma today announced that it has appointed John Cunningham, ... Advisory Board. , Dr. Cunningham is Professor of Nephrology ... at the Royal Free Hospital, London. His early training ... in The University of London and Washington University ...
... , SLINGERLANDS, N.Y., Oct. 15 Sabre Technical Services ... to the problems experienced by U.S. homeowners and builders ... Sabre,s solution is an adaptation of its patented chlorine ... and smaller buildings. , Sabre has a long history ...
... ... Inc. announced that it completed its pre-IND meeting with the U.S. Food ... evaluate the safety and efficacy of Stemedica,s high potency proprietary allogeneic mesenchymal ... Based on a meeting October 13, 2009 with the FDA, Stemedica is ...
Cached Biology Technology:Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 2Cytochroma Appoints Dr. John Cunningham to its Scientific Advisory Board 3Sabre Announces Roll-Out of Permanent Solution to Chinese Drywall Problems 2Sabre Announces Roll-Out of Permanent Solution to Chinese Drywall Problems 3Stemedica Completes Meeting with the FDA 2Stemedica Completes Meeting with the FDA 3
BAI-1 (T-20)...
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Biology Products: